deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT04009109

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma

Sponsor: Alliance Foundation Trials, LLC.

Conditions Myeloma, Multiple
Interventions Daratumumab Injection Dexamethasone Ixazomib Lenalidomide
Updated 17 times since 2019 Last updated: Dec 16, 2025 Started: Oct 21, 2020 Primary completion: Dec 31, 2026 Completion: Jun 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04009109, this PHASE2 trial focuses on Myeloma, Multiple and remains ongoing. Sponsored by Alliance Foundation Trials, LLC., it has been updated 17 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Aug 2019 – ~Feb 2020 · 6 months · monthly snapshot~Feb 2020 – ~Jun 2020 · 4 months · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Jun 2023 · 4 months · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Mar 2024 · 7 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Jan 2026 · 8 months · monthly snapshot~Jan 2026 – present · 7 months · monthly snapshot

Change History

17 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. May 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 12 earlier versions

  1. Aug 2023 — Mar 2024 [monthly]

    Recruiting PHASE2

  2. Jun 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  3. Feb 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  4. Sep 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  5. Apr 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  6. Sep 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  7. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Jan 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE2

  9. Aug 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

  10. Jun 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE2

  11. Feb 2020 — Jun 2020 [monthly]

    Not Yet Recruiting PHASE2

  12. Aug 2019 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alliance Foundation Trials, LLC.
  • Celgene Corporation
  • Janssen Scientific Affairs, LLC
  • Takeda
Data source: Alliance Foundation Trials, LLC.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations